Investigators reported initial clinical testing of allogeneic induced pluripotent stem cell (iPSC)‑derived invariant natural killer T (iNKT) cells in recurrent head and neck cancer. The Phase I study explores safety and early efficacy of off‑the‑shelf, engineered iNKT cells aimed at providing an alternative to autologous cell therapy while avoiding chronic immunosuppression. Early signals and translational data will inform dose escalation and manufacturing controls; the program represents a broader industry trend toward allogeneic, iPSC‑based immunotherapies for solid tumors.